Who
Joshua Reed
SVP, Chief Financial Officer
Company insider
Files Form 4 as: SVP, Chief Financial Officer, Alkermes; Director, Scholar Rock Holding; Chief Financial Officer, Omega Therapeutics; Chief Financial Officer, Aldeyra Therapeutics.
In numbers
- Trades disclosed
- 41
- Buys
- 1
- Sells
- 2
- Bought
- $15K
- Sold
- $489K
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 30 Jul 2018
- Last trade
- 8 Oct 2026
- Last filed
- 9 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Oct 2026filed 9 Oct 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | —9,164 | filing |
| 8 Oct 2026filed 9 Oct 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code F | $163K4,069 at $40.11 | filing |
| 8 Oct 2026filed 9 Oct 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —9,164 | filing |
| 1 Jul 2026filed 6 Jul 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $113K2,105 at $53.50 | filing |
| 1 Jul 2026filed 6 Jul 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $51K948 at $54.28 | filing |
| 1 Jul 2026filed 6 Jul 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $113K2,105 at $53.50 | filing |
| 1 Jul 2026filed 6 Jul 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $51K948 at $54.28 | filing |
| 4 Jun 2026filed 8 Jun 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —6,839 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,310 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,310 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —6,839 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —66,430 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,854 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —66,430 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,854 at $0.00 | filing |
| 8 Oct 2025filed 10 Oct 2025 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —158,743 at $0.00 | filing |
| 8 Oct 2025filed 10 Oct 2025 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —36,656 at $0.00 | filing |
| 29 May 2025filed 30 May 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $145K4,900 at $29.68 | filing |
| 29 May 2025filed 30 May 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $15K500 at $30.04 | filing |
| 22 May 2025filed 23 May 2025 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,206 at $0.00 | filing |
News
Scholar Rock Resubmits Marketing Authorisation Application For ApitegromabSRRK · rttnews.com · 8 Oct 2026
0 headlines in the last 90 days name Joshua Reed; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.